HLB's liver cancer therapy proves effective across all age groups in new study
HLB Group's liver cancer combination therapy showed consistent treatment benefits regardless of patient age, including in patients under 40, according to a new subgroup analysis to be presented this week at an international cancer conference. Elevar Therapeutics, HLB's U.S. subsidiary, will present an age-based post-hoc analysis of its global Phase 3 CARES-310 trial in a poster session at the…
A new study reveals that HLB Group's liver cancer therapy proved effective across all age groups, according to a subgroup analysis to be presented at an international cancer conference. The combination therapy, involving rivoceranib and camrelizumab, showed promising results in a Phase 3 trial conducted by Elevar Therapeutics, the company's U.S. subsidiary.
In patients under 50, the median overall survival was 21.5 months, compared to 15.2 months with the standard treatment sorafenib. Similarly, for patients aged 50 and older, median overall survival was 23.9 months, indicating consistent benefits regardless of age. The therapy also demonstrated comparable gains in median progression-free survival.
Written by urgent.news from The Korea Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
